Premium
Factor V L eiden
Author(s) -
Van Cott Elizabeth M.,
Khor Bernard,
Zehnder James L.
Publication year - 2016
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24222
Subject(s) - factor v leiden , bivalirudin , thrombophilia , medicine , activated protein c resistance , argatroban , rivaroxaban , lupus anticoagulant , direct thrombin inhibitor , factor v , dabigatran , immunology , thrombin , platelet , thrombosis , warfarin , venous thrombosis , percutaneous coronary intervention , myocardial infarction , atrial fibrillation
Factor V Leiden (FV Leiden ) is a common hereditary thrombophilia that causes activated protein C (APC) resistance. This review describes many of the most fascinating features of FV Leiden , including background features, mechanisms of hypercoagulability, the founder mutation concept, the “FV Leiden paradox,” synergistic interaction with other thrombotic risk factors, the intertwined relationship between FV Leiden and APC resistance testing, and other, uncommon mutations implicated in causing APC resistance. In addition, there are several conditions where laboratory tests for APC resistance and FV Leiden are or can be discrepant, including lupus anticoagulants, anticoagulants such as direct thrombin inhibitors (dabigatran, argatroban, and bivalirudin) and rivaroxaban, as well as pseudohomozygous, pseudo‐wildtype, liver transplant, and bone marrow transplant patients. The laboratory test error rate for FV Leiden is also presented. Am. J. Hematol. 91:46–49, 2016. © 2015 Wiley Periodicals, Inc.